Ropinirole
Ropinirole (ropinirole) is a small molecule pharmaceutical. Ropinirole was first approved as Requip on 1997-09-19. It is used to treat parkinson disease in the USA. The pharmaceutical is active against D(3) dopamine receptor and D(2) dopamine receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| nervous system diseases | D009422 |
Trade Name
FDA
EMA
Ropinirole (discontinued: Requip, Ropinirole)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| requip | New Drug Application | 2011-12-27 |
| requipxl | New Drug Application | 2009-12-18 |
| ropinirole | ANDA | 2025-10-02 |
| ropinirole hydrochloride | ANDA | 2025-05-30 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| parkinson disease | EFO_0002508 | D010300 | G20 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
80 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Parkinson disease | D010300 | EFO_0002508 | G20 | 3 | 4 | 21 | 9 | 4 | 40 |
| Restless legs syndrome | D012148 | EFO_0004270 | G25.81 | 3 | 3 | 9 | 5 | 5 | 25 |
| Psychomotor agitation | D011595 | — | — | 2 | 2 | 8 | 5 | 3 | 20 |
| Syndrome | D013577 | — | — | 1 | 2 | 8 | 4 | 3 | 18 |
| Depression | D003863 | — | F33.9 | — | — | 1 | 2 | — | 3 |
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | — | — | — | 2 | — | 2 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | — | — | — | 1 | 1 | 2 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | — | — | — | 1 | 1 | 2 |
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | — | — | 1 | — | 1 |
| Fibrosis | D005355 | — | — | — | — | — | 1 | — | 1 |
Show 7 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | 1 | 1 | 1 | — | 1 | 4 |
| Dyskinesias | D020820 | — | G24 | — | — | 1 | — | — | 1 |
| Sleep wake disorders | D012893 | — | G47 | — | — | 1 | — | — | 1 |
| Parasomnias | D020447 | — | G47.5 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | 1 | — | — | 1 | 2 |
| Cocaine-related disorders | D019970 | — | F14 | — | 1 | — | — | — | 1 |
| Chronic renal insufficiency | D051436 | — | N18 | — | 1 | — | — | — | 1 |
| Prolactinoma | D015175 | — | — | 1 | 1 | — | — | — | 1 |
| Hyperprolactinemia | D006966 | — | E22.1 | 1 | 1 | — | — | — | 1 |
| Epilepsy | D004827 | EFO_0000474 | G40.9 | — | 1 | — | — | — | 1 |
| Myoclonic epilepsies | D004831 | EFO_1001900 | G40.4 | — | 1 | — | — | — | 1 |
| Unverricht-lundborg syndrome | D020194 | Orphanet_308 | G40.3 | — | 1 | — | — | — | 1 |
| Progressive myoclonic epilepsies | D020191 | Orphanet_98261 | — | — | 1 | — | — | — | 1 |
| Edema | D004487 | — | R60.9 | — | 1 | — | — | — | 1 |
Show 4 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 4 | — | — | — | — | 4 |
| Pharmacogenomic testing | D000071185 | — | — | 3 | — | — | — | — | 3 |
| Malnutrition | D044342 | EFO_0008572 | E40-E46 | 2 | — | — | — | — | 2 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Shy-drager syndrome | D012791 | EFO_1001050 | — | — | — | — | — | 1 | 1 |
| Multiple system atrophy | D019578 | — | — | — | — | — | — | 1 | 1 |
| Nervous system diseases | D009422 | — | G00-G99 | — | — | — | — | 1 | 1 |
| Parkinsonian disorders | D020734 | — | G20.C | — | — | — | — | 1 | 1 |
| Neurologic gait disorders | D020233 | — | R26.1 | — | — | — | — | 1 | 1 |
| Huntington disease | D006816 | Orphanet_399 | G10 | — | — | — | — | 1 | 1 |
| Progressive supranuclear palsy | D013494 | EFO_0002512 | G23.1 | — | — | — | — | 1 | 1 |
| Corticobasal degeneration | D000088282 | — | G31.85 | — | — | — | — | 1 | 1 |
| Diabetes complications | D048909 | — | — | — | — | — | — | 1 | 1 |
| Renal dialysis | D006435 | EFO_0010690 | Z99.2 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Ropinirole |
| INN | ropinirole |
| Description | Ropinirole is a member of indolones and a tertiary amine. It has a role as a dopamine agonist, an antiparkinson drug, a central nervous system drug and an antidyskinesia agent. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCCN(CCC)CCc1cccc2c1CC(=O)N2 |
Identifiers
| PDB | — |
| CAS-ID | 91374-21-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL589 |
| ChEBI ID | 8888 |
| PubChem CID | 5095 |
| DrugBank | DB00268 |
| UNII ID | 030PYR8953 (ChemIDplus, GSRS) |
Target
Variants
No data
Financial
Revenue by drug
$
€
ÂŁ
â‚Ł
No data
Estimated US medical usage
Ropinirole
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 4,408 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
11,876 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use